Results 11 to 20 of about 3,398 (179)

Delayed Hypersensitivity with Ferric Carboxymaltose [PDF]

Journal of Clinical and Diagnostic Research, 2017
Ferric Carboxymaltose (FCM) is widely used in the treatment of anaemia of Chronic Kidney Disease (CKD). The clinicians must be alert of the rare adverse events such as hypersensitivity with subsequent doses of FCM. Here, we report a case of a 59-year-old
Surabhi Sridhara, Rajesh Vilakkathala, Ravindra Prabhu, Karan Saraf   +3 more
doaj   +2 more sources

Intravenous ferric carboxymaltose is associated with lowering of plasma phosphate levels in patients with gastric bypass surgery: a retrospective case series

Swiss Medical Weekly
AIMS: Bariatric surgery induces several micronutrient deficiencies that require supplementation. For iron, parenteral infusions are usually preferred over oral supplementation.
Cindy Pereira Portela, Lucie Favre, Isabella Locatelli, Olivier Bonny   +3 more
doaj   +2 more sources

Acute hypersensitivity reaction following intravenous ferric carboxymaltose injection for iron deficiency anaemia: a case report.

Critical Care Innovations, 2023
Ferric carboxymaltose (FCM) is a non-dextran iron preparation used for intravenous treatment of iron deficiency anaemia (IDA) in adult patients with intolerance or poor response to oral iron therapy.
Neeraj Kumar, Preeti Bala Gautam, Sarfaraz Ahmad, Danish Qutub, Indira Prasad   +4 more
doaj   +2 more sources

Retrospective Case Reports of Anemic Pregnant Women Receiving Intravenous Ferric Carboxymaltose: Experience from a Tertiary Hospital in Spain [PDF]

Obstetrics and Gynecology International, 2016
Iron deficiency and iron deficiency anemia during pregnancy call for safe treatment options that raise maternal hemoglobin levels and counterbalance iron demand and blood volume expansion while minimizing risks for the growing fetus.
Rafael Aporta Rodriguez, Mariola García Montero, Jose Pablo Lorente Aporta, Carolina Gallego Luque, Alfonso Chacón Mayor, Jose Aragón Ruiz, Virginia Torres Degayón, Claudia García Jimenez, Guadalupe Sanchez Sanchez   +8 more
doaj   +2 more sources

Case Report: High-Dose Ferric Carboxymaltose as an Antianaemic Agent to Avoid Haemotransfusions after Total Hip Replacement

Medicina
This article highlights a case of high-dose ferric carboxymaltose (Ferinject®) for the treatment of perioperative iron deficiency anaemia in a 39-year-old patient with dysplastic coxarthrosis.
Maiya Konkayeva, Assiya Kadralinova, Nazerke Zhanarystan, Nurlan Akhatov, Aidos Konkayev   +4 more
doaj   +2 more sources

Osteomalacia Following Iron Infusion Therapy in a Patient With Rendu‐Osler‐Weber Syndrome: F‐18‐FDG PET/CT Discrimination of a Stress Fracture in the Setting of a Musculoskeletal Tumor Mimic

Clinical Case Reports
This case report highlights a rare occurrence of osteomalacia induced by hypophosphatemia secondary to ferric carboxymaltose (FCM) therapy in a patient with hereditary hemorrhagic telangiectasia (HHT, or Rendu‐Osler‐Weber syndrome).
Ioannis S. Vasios, Pipitsa N. Valsamaki, Konstantinos Tilkeridis, Savvas Deftereos, Efthymios Iliopoulos   +4 more
doaj   +2 more sources

Incidence of adverse events in iron-deficient pregnant women and surgical patients undergoing intravenous iron treatment with ferric isomaltose or ferric carboxymaltose: A systematic review. [PDF]

Transfusion
Transfusion, Volume 66, Issue 4, Page 840-852, April 2026.
Heger D, Volkmann J, Weibel S, Stoevesandt J, Walzer V, Kranke P, Meybohm P, Stangl S.   +7 more
europepmc   +2 more sources

Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function [PDF]

, 2023
Background: Reduced kidney function is common among patients with heart failure. In patients with heart failure and/or kidney disease, iron deficiency is an independent predictor of adverse outcomes.
Jankowska, Ewa A, Macdougall, IC, Wächter, S, Filippatos, Gerasimos, Kumpeson, Vasuki, Austin G. Stack, Butler, Javed, Bridget-Anne Kirwan, Anker, SD, Wheeler, DC, Ruschitzka, Frank, Rosano, G, Giuseppe Rosano, Ewa A. Jankowska, Iain C. Macdougall, Ponikowski, Piotr, Anker, Stefan D., Macdougall, Iain C, Jankowska, EA, Jankowska, Ewa A., van der Meer, P, Göhring, Udo-Michael, Vasuki Kumpeson, Kirwan, Bridget-Anne, Rosano, Giuseppe, Metra, Marco, Filippatos, G, Ruschitzka, F, Javed Butler, Macdougall, Iain C., Göhring, U-M, Anker, Stefan D, Gerasimos Filippatos, Frank Ruschitzka, Butler, J, Göhring, Udo Michael, Ponikowski, P, Wheeler, David C, Wächter, Sandra, Stefan D. Anker, Stack, AG, Kirwan, B-A, Stack, Austin G, David C. Wheeler, Piotr Ponikowski, Peter van der Meer, Sandra Wächter, Kumpeson, V, Marco Metra, Stack, Austin G., Kirwan, Bridget Anne, Metra, M, Udo-Michael Göhring, van der Meer, Peter, Wheeler, David C.   +54 more
core   +5 more sources

Evaluating the Risk of Hypophosphatemia with Ferric Carboxymaltose and the Recommended Approaches for Management: A Consensus Statement. [PDF]

J Clin Med
Background/Objectives: The development of hypophosphatemia has been associated with intravenous iron products, with the rate of hypophosphatemia found to be higher with ferric carboxymaltose.
Rosano G, Ezekowitz J, Nemeth E, Ponikowski P, Rauner M, Rauner M, Seid M, Spahn DR, Stein J, Wish J, Mentz RJ.   +10 more
europepmc   +2 more sources

Iron Status and Analysis of Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients with Inflammatory Bowel Disease [PDF]

, 2011
Background and Aims:We analyzed iron deficiency and the therapeutic response following intravenous ferric carboxymaltose in a large single-center inflammatory bowel disease (IBD) cohort.
Brand, Stephan, Burkhard Göke, Breiteneicher, Simone, Göke, Burkhard, Ochsenkühn, Thomas, Fabian Schnitzler, Stephan Brand, Maria Weidinger, Thomas Ochsenkühn, Simone Breiteneicher, Beigel, Florian, Weidinger, Maria, Schnitzler, Fabian, Löhr, Beate, Seiderer, Julia, Laubender, Rüdiger P., Beate Löhr, Tillack, Cornelia, Cornelia Tillack, Florian Beigel, Julia Seiderer, Rüdiger P. Laubender   +21 more
core   +1 more source